In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis

Abstract

Objective

The term benign multiple sclerosis (BMS) is referred to patients who have a mild or absent disability several years after disease clinical onset. Axonal damage can be measured in vivo using proton MR spectroscopy (¹H-MRS). In this study, we quantified the severity of “global” axonal damage in BMS and early relapsing–remitting (RR) MS patients, using whole brain N-acetylaspartate (WBNAA) ¹H-MRS, to better elucidate the structural correlates of a non-disabling disease evolution.

Methods

WBNAA concentration was measured in 37 patients with BMS (mean disease duration 22.3 years) and 17 patients with early RRMS (mean disease duration 4.0 years), using an unlocalized ¹H-MRS sequence. Dual echo and T1-weighted scans were also obtained to measure T2-hyperintense lesion volume (TLV) and normalized brain volume (NBV).

Results

TLV was higher in BMS (mean TLV = 13.1 mL) than in early RRMS patients (mean TLV = 7.2 mL) (P = 0.018), whereas neither NBV (mean NBV: 1491.0 mL in BMS vs 1520.3 mL in RRMS) nor WBNAA concentration (mean WBNAA: 10.5 mmol in BMS vs 11.4 mmol in RRMS) significantly differed between the two groups. In MS patients, no correlation was found between WBNAA concentration and Expanded Disability Status Scale (EDSS), TLV and NBV.

Conclusions

The similar WBNAA concentrations seen in BMS and early RRMS patients fit with the notion that a non-disabling long-term evolution of MS may be due, at least in part, to non-progression of pathology. Such a condition seems to be independent from MRI-visible lesions burden.

Keywords

axonal damage benign MR spectroscopy multiple sclerosis relapsing-remitting

Get full access to this article

View all access options for this article.

References

1 Ramsaransing G De Keyser J . Benign course in multiple sclerosis. A review. Acta Neurol Scand 2006; 113: 359–369.

2 Lublin FD Reingold SC . The National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907–911.

3 Dutta R Trapp BD . Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007; 68: S22–S31.

4 Brass SD Narayanan S Antel JP Lapierre Y Collins L Arnold DL . Axonal damage in multiple sclerosis patients with high versus low expanded disability status scale score. Can J Neurol Sci 2004; 31: 225–228.

5 Davie CA Barker GJ Thompson AJ Tofts PS McDonald WI Miller DH . 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 63: 736–742.

6 Davie CA Silver NC Barker GJ . Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? J Neurol Neurosurg Psychiatry 1999; 67: 710–715.

7 Falini A Calabrese G Filippi M . Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability. AJNR Am J Neuroradiol 1998; 19: 223–229.

8 Strasser-Fuchs S Enzinger C Ropele S Wallner M Fazekas F . Clinically benign multiple sclerosis despite large T2 lesion load: Can we explain this paradox? Mult Scler 2008; 14: 205–211.

9 Gonen O Viswanathan AK Catalaa I Babb J Udupa J Grossman RI . Total brain N-acetylaspartate concentration in normal, age-grouped females: quantification with non-echo proton NMR spectroscopy. Magn Reson Med 1998; 40: 684–689.

10.

10 Gonen O Catalaa I Babb JS . Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology 2000; 54: 15–19.

11.

11 Ge Y Gonen O Inglese M Babb JS Markowitz CE Grossman RI . Neuronal cell injury precedes brain atrophy in multiple sclerosis. Neurology 2004; 62: 624–627.

12.

12 Pulizzi A Rovaris M Judica E . Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study. Arch Neurol 2007; 64: 1163–1168.

13.

13 Polman CH Reingold SC Edan G . Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58: 840–846.

14.

14 Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.

15.

15 Rovaris M Filippi M Calori G . Intra-observer reproducibility in measuring new putative markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. J Neurol 1997; 18: 895–901.

16.

16 Smith SM Zhang Y Jenkinson M . Accurate, robust and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17: 479–489.

17.

17 Rigotti DJ Inglese M Gonen O . Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders. AJNR Am J Neuroradiol 2007; 28: 1843–1849.

18.

18 Rigotti DJ Inglese M Babb JS . Serial whole-brain N-acetylaspartate concentration in healthy young adults. AJNR Am J Neuroradiol 2007; 28: 1650–1651.

19.

19 Filippi M Bozzali M Rovaris M . Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003; 126: 433–437.

20.

20 Rocca MA Mezzapesa DM Falini A . Evidence for axonal pathology and adaptive cortical reorganization in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Neuroimage 2003; 18: 847–855.

21.

21 Rovaris M Gallo A Falini A . Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis. Arch Neurol 2005; 62: 898–902.

22.

22 Falini A Bozzali M Magnani G . A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment. Neuroimage 2005; 26: 1159–1163.

23.

23 Inglese M Ge Y Filippi M Falini A Grossman RI Gonen O . Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. Neuroimage 2004; 21: 1825–1829.

24.

24 Cohen BA Inglese M Rusinek H Babb JS Grossman RI Gonen O . Proton MR spectroscopy and MRI-volumetry in mild traumatic brain injury. AJNR Am J Neuroradiol 2007; 28: 907–913.

25.

25 Benedetti B Rigotti DJ Liu S Filippi M Grossman RI Gonen O . Reproducibility of the whole-brain N-acetylaspartate level across institutions, MR scanners, and field strengths. AJNR Am J Neuroradiol 2007; 28: 72–75.

26.

26 Chard DT Griffin CM McLean MA . Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 2002; 125: 2342–2352.

27.

27 Dalton CM Chard DT Davies GR . Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127: 1101–1107.

28.

28 Rovaris M Gambini A Gallo A . Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. Neurology 2005; 65: 1626–1630.

29.

29 De Stefano N Battaglini M Stromillo ML . Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain 2006; 129: 2008–2016.

30.

30 Mainero C De Stefano N Iannucci G . Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology 2001; 56: 1331–1334.

31.

31 De Stefano N Narayanan S Francis GS . Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001; 58: 65–70.

32.

32 Barkhof F . The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002; 15: 239–245.